Yes, you can and should order a lipoprotein(a) measurement for this patient
Measuring Lp(a) is independent of statin therapy decisions and provides valuable cardiovascular risk information that should be obtained at least once in every adult's lifetime. 1, 2
Why Lp(a) Testing is Appropriate Regardless of Statin Use
The key point here is that Lp(a) measurement serves a different purpose than deciding whether to prescribe statins. Lp(a) is a genetically determined risk factor that remains constant throughout life and is largely unaffected by lifestyle modifications or most lipid-lowering therapies 3, 4. In fact, statins have inconsistent effects on Lp(a) and may even cause elevation in some patients 4.
Current Guideline Recommendations Support Testing
Multiple guidelines now recommend measuring Lp(a) at least once in specific populations 3, 4, 1:
High-priority indications for Lp(a) testing include:
- Premature cardiovascular disease or stroke
- Family history of premature CVD or elevated Lp(a)
- Familial hypercholesterolemia or other genetic dyslipidemias
- Recurrent or rapidly progressive vascular disease despite treatment
- Intermediate to high cardiovascular risk (≥3% 10-year risk of fatal CVD by European guidelines or ≥10% by US guidelines) 4
The most recent 2026 ACC/AHA guidelines specifically address evaluation and management of elevated Lp(a) as part of comprehensive dyslipidemia management 1.
Clinical Utility Beyond Statin Therapy
Elevated Lp(a) (>50 mg/dL or >75 nmol/L) affects approximately 20% of the population and represents an independent cardiovascular risk factor 3, 5, 2. When identified, this information:
Refines overall cardiovascular risk assessment - Patients with elevated Lp(a) move into higher risk categories, which may justify more aggressive management of other modifiable risk factors 4
Guides intensification of other therapies - Even without statin use, knowing Lp(a) status helps determine how aggressively to manage blood pressure, lifestyle factors, and whether to consider aspirin or other interventions 2
Identifies candidates for emerging therapies - Antisense oligonucleotides and siRNA agents that reduce Lp(a) by up to 90% are in late-stage trials, and patients with very high Lp(a) may benefit from these treatments when approved 5, 6, 2
Informs family screening - Since Lp(a) is genetically determined, elevated levels warrant consideration of testing family members 3
Management Without Statins
If Lp(a) is elevated in a patient declining statin therapy, management should focus on:
- Comprehensive risk factor modification - Aggressive blood pressure control, smoking cessation, diabetes management, weight optimization 4, 7
- Consider niacin - Currently the most recommended drug for Lp(a) reduction (30-35% reduction), though evidence for cardiovascular outcomes is limited 4
- PCSK9 inhibitors - Reduce Lp(a) by up to 30% and have proven cardiovascular benefits, though typically used after statins 6
- Aspirin - May provide 10-20% Lp(a) reduction and antithrombotic benefit in select high-risk patients 4, 2
Common Pitfall to Avoid
Do not conflate Lp(a) testing with statin decision-making. The fact that a patient declines statin therapy does not negate the value of understanding their Lp(a)-mediated cardiovascular risk. Lp(a) provides independent prognostic information that remains relevant regardless of other treatment choices 7, 8.
The measurement should be done once using an isoform-insensitive assay, as Lp(a) levels remain relatively stable throughout life 3, 9. Consider thresholds of >30 mg/dL (75 nmol/L) as elevated for primary prevention populations, or >50 mg/dL (100-125 nmol/L) for higher-risk populations 3, 4.